{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:07:45Z","timestamp":1781302065141,"version":"3.54.1"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00267","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T04:18:17Z","timestamp":1518581897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Jodi","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"B1","volume-title":"Cancer Facts & Figures","author":"Society","year":"2017"},{"key":"B2","volume-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide","author":"Ferlay","year":"2013"},{"key":"B3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0140-6736(03)12777-8","article-title":"Hodgkin\u2019s lymphoma","volume":"361","author":"Yung","year":"2003","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.critrevonc.2012.07.002","article-title":"Hodgkin lymphoma","volume":"85","author":"Gobbi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coi.2015.11.001","article-title":"Immunosurveillance and immunotherapy of tumors by innate immune cells","volume":"38","author":"Iannello","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcancer.2013.07.002","article-title":"The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component","volume":"24","author":"Liu","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.878","article-title":"Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma","volume":"27","author":"Schreck","year":"2009","journal-title":"Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/ijc.24389","article-title":"Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed\u2013Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin\u2019s lymphoma","volume":"125","author":"Cattaruzza","year":"2009","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/0008-5472.CAN-05-3252","article-title":"Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin\u2019s lymphoma","volume":"66","author":"Chemnitz","year":"2006","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/blood-2006-12-064360","article-title":"RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma","volume":"110","author":"Chemnitz","year":"2007","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1182\/blood-2007-01-066100","article-title":"Galectin-1 mediated suppression of Epstein\u2013Barr virus specific T-cell immunity in classic Hodgkin lymphoma","volume":"110","author":"Gandhi","year":"2007","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-dependent secretion of galectin-1 by Reed\u2013Sternberg cells fosters immune privilege in classical Hodgkin lymphoma","volume":"104","author":"Juszczynski","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","article-title":"Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands","volume":"68","author":"Wendel","year":"2008","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ijc.10399","article-title":"Common and differential chemokine expression patterns in RS cells of NLP, EBV positive and negative classical Hodgkin lymphomas","volume":"99","author":"Maggio","year":"2002","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1080\/1042819031000082984","article-title":"Differential chemokine, chemokine receptor and cytokine expression in Epstein\u2013Barr virus-associated lymphoproliferative diseases","volume":"44","author":"Ohshima","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0124614","DOI":"10.1371\/journal.pone.0124614","article-title":"A multi-component model of Hodgkin\u2019s lymphoma","volume":"10","author":"Staege","year":"2015","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nri3799","article-title":"Balancing natural killer cell activation through paired receptors","volume":"15","author":"Martinet","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.4049\/jimmunol.164.12.6244","article-title":"IL-2 activation of NK cells: involvement of MKK1\/2\/ERK but not p38 kinase pathway","volume":"164","author":"Yu","year":"2000","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16606","DOI":"10.1073\/pnas.0407522101","article-title":"Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs","volume":"101","author":"Ferlazzo","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10875-010-9382-9","article-title":"TL1A selectively enhances IL-12\/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets","volume":"30","author":"Heidemann","year":"2010","journal-title":"J Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni.2936","article-title":"The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells","volume":"15","author":"Marcais","year":"2014","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.4049\/jimmunol.170.11.5464","article-title":"IL-21 in synergy with IL-15 or IL-18 enhances IFN- production in human NK and T cells","volume":"170","author":"Strengell","year":"2003","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/2051-1426-3-S2-P233","article-title":"Interleukin-21 activates natural killer cell activity against cetuximab-coated pancreatic tumor cells","volume":"3","author":"McMichael","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming","volume":"5","author":"Martin-Fontecha","year":"2004","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK cells: an update","volume":"196","author":"Michel","year":"2016","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.20051474","article-title":"Natural killer cell behavior in lymph nodes revealed by static and real-time imaging","volume":"203","author":"Bajenoff","year":"2006","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.4049\/jimmunol.1100330","article-title":"CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation","volume":"186","author":"Beziat","year":"2011","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","article-title":"CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset","volume":"116","author":"Lopez-Verges","year":"2010","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fimmu.2015.00259","article-title":"Differential cytotoxicity but augmented IFN-gamma secretion by NK cells after interaction with monocytes from humans, and those from wild type and myeloid-specific COX-2 knockout mice","volume":"6","author":"Tseng","year":"2015","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/1547691X.2013.877104","article-title":"Natural killer cells as effectors of selection and differentiation of stem cells: role in resolution of inflammation","volume":"11","author":"Jewett","year":"2014","journal-title":"J Immunotoxicol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The broad spectrum of human natural killer cell diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1080\/10428190500220654","article-title":"Tumor-infiltrating cells as a prognostic factor in Hodgkin\u2019s lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients","volume":"46","author":"Alvaro-Naranjo","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF00320582","article-title":"In situ quantification of T-cell subsets, NK-like cells and macrophages in Hodgkin\u2019s disease: quantity and quality of infiltration density depends on histopathological subtypes","volume":"53","author":"Gattringer","year":"1986","journal-title":"Blut"},{"key":"B41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1399-0039.2008.01005.x","article-title":"HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin\u2019s lymphoma","volume":"71","author":"Diepstra","year":"2008","journal-title":"Tissue Antigens"},{"key":"B42","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/bjc.1982.274","article-title":"Natural killer (NK) activity in the spleen of patients with Hodgkin\u2019s disease and controls","volume":"46","author":"Al Sam","year":"1982","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3109\/10428199909058479","article-title":"Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin\u2019s disease","volume":"34","author":"Ayoub","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/1097-0142(19821201)50:11<2333::AID-CNCR2820501119>3.0.CO;2-W","article-title":"Low natural killer cell activity in patients with malignant lymphoma","volume":"50","author":"Tursz","year":"1982","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/0277-5379(82)90087-6","article-title":"Depressed spontaneous natural killing and interferon augmentation in patients with malignant lymphoma","volume":"18","author":"Hawrylowicz","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/0277-5379(85)90215-9","article-title":"An assessment of natural cell-mediated cytotoxicity in patients with malignant lymphoma","volume":"21","author":"Healy","year":"1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1002\/1097-0142(19851215)56:12<2799::AID-CNCR2820561215>3.0.CO;2-W","article-title":"Natural killer cell activity during the course of disease in patients with Hodgkin\u2019s disease","volume":"56","author":"Frydecka","year":"1985","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood.V69.6.1686.1686","article-title":"A killing defect of natural killer cells with the absence of natural killer cytotoxic factors in a child with Hodgkin\u2019s disease","volume":"69","author":"Komiyama","year":"1987","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/bjc.1990.261","article-title":"Natural killer and lymphokine activated killer cell functions in Hodgkin\u2019s disease","volume":"62","author":"Rajaram","year":"1990","journal-title":"Br J Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1046\/j.1365-2141.1999.01129.x","article-title":"The difference in NK-cell activity between patients with non-Hodgkin\u2019s lymphomas and Hodgkin\u2019s disease","volume":"104","author":"Konjevic","year":"1999","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/mt.2013.14","article-title":"Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients","volume":"21","author":"Reiners","year":"2013","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/BF01742314","article-title":"Impairment in proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2-producing cells in Hodgkin\u2019s disease","volume":"34","author":"Damle","year":"1991","journal-title":"Cancer Immunol Immunother"},{"key":"B54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V64.2.386.bloodjournal642386","article-title":"Association of an interleukin abnormality with the T cell defect in Hodgkin\u2019s disease","volume":"64","author":"Ford","year":"1984","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/1097-0142(19870601)59:11<1906::AID-CNCR2820591111>3.0.CO;2-A","article-title":"Immunologic profile in patients with Hodgkin\u2019s disease in complete remission","volume":"59","author":"Liberati","year":"1987","journal-title":"Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/j.1365-2141.2002.03572.x","article-title":"Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin\u2019s disease with proliferative activity, interleukin 2 and interferon-gamma production","volume":"118","author":"Kosmaczewska","year":"2002","journal-title":"Br J Haematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/ijc.2910500206","article-title":"Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin\u2019s disease","volume":"50","author":"Damle","year":"1992","journal-title":"Int J Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bjc.1995.354","article-title":"Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2","volume":"72","author":"Gooding","year":"1995","journal-title":"Br J Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1097-0142(19930701)72:1<201::AID-CNCR2820720136>3.0.CO;2-V","article-title":"Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome","volume":"72","author":"Ambrosetti","year":"1993","journal-title":"Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/bjc.1998.163","article-title":"Soluble interleukin-2 receptors (sIL-2R) in Hodgkin\u2019s disease: outcome and clinical implications","volume":"77","author":"Viviani","year":"1998","journal-title":"Br J Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.4049\/jimmunol.1402898","article-title":"IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1","volume":"195","author":"Hsu","year":"2015","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.4049\/jimmunol.170.10.5260","article-title":"Different modes of IL-10 and TGF- to inhibit cytokine-dependent IFN- production: consequences for reversal of lipopolysaccharide desensitization","volume":"170","author":"Schroder","year":"2003","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1093\/brain\/awl205","article-title":"TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells","volume":"129","author":"Eisele","year":"2006","journal-title":"Brain"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.4049\/jimmunol.1202693","article-title":"Neuroblastoma-derived TGF-beta1 modulates the chemokine receptor repertoire of human resting NK cells","volume":"190","author":"Castriconi","year":"2013","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.4049\/jimmunol.172.12.7335","article-title":"Elevated TGF- 1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients","volume":"172","author":"Lee","year":"2004","journal-title":"J Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ni.3800","article-title":"Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells","volume":"18","author":"Gao","year":"2017","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/leu.2014.345","article-title":"The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells","volume":"29","author":"Ullrich","year":"2015","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/path.1745","article-title":"Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma","volume":"206","author":"Teichmann","year":"2005","journal-title":"J Pathol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/10428190009087027","article-title":"The role of chemokines in Hodgkin\u2019s disease","volume":"38","author":"Teruya-Feldstein","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.166.11.6477","article-title":"Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire","volume":"166","author":"Campbell","year":"2001","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4049\/jimmunol.175.1.61","article-title":"Human first-trimester trophoblast cells recruit CD56brightCD16\u2212 NK cells into decidua by way of expressing and secreting of CXCL12\/stromal cell-derived factor 1","volume":"175","author":"Wu","year":"2005","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed\u2013Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0165-0378(99)00031-5","article-title":"P49, a putative HLA-G1 specific inhibitory NK receptor belonging to the immunoglobulin superfamily","volume":"43","author":"Cantoni","year":"1999","journal-title":"J Reprod Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"8856","DOI":"10.1073\/pnas.1431057100","article-title":"Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G","volume":"100","author":"Shiroishi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.prp.2011.11.004","article-title":"Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications","volume":"208","author":"Kren","year":"2012","journal-title":"Pathol Res Pract"},{"key":"B77","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/85321","article-title":"Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells","volume":"2","author":"Groh","year":"2001","journal-title":"Nat Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.immuni.2007.10.010","article-title":"Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells","volume":"27","author":"Pogge von Strandmann","year":"2007","journal-title":"Immunity"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2011-07-370841","article-title":"High ERp5\/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas","volume":"119","author":"Zocchi","year":"2012","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"34295","DOI":"10.1074\/jbc.M113.483602","article-title":"A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells","volume":"288","author":"Binici","year":"2013","journal-title":"J Biol Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jcp.37.7.767","article-title":"Reed\u2013Sternberg\/lymphocyte rosette: lymphocyte subpopulations as defined by monoclonal antibodies","volume":"37","author":"Morris","year":"1984","journal-title":"J Clin Pathol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/modpathol.2012.217","article-title":"Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma","volume":"26","author":"Hartmann","year":"2013","journal-title":"Mod Pathol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1084\/jem.20031080","article-title":"c-FLIP mediates resistance of Hodgkin\/Reed\u2013Sternberg cells to death receptor-induced apoptosis","volume":"199","author":"Mathas","year":"2004","journal-title":"J Exp Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/00000478-200103000-00014","article-title":"Fas ligand expression in Hodgkin lymphoma","volume":"25","author":"Verbeke","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1006\/cyto.1996.0181","article-title":"Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK\/LAK cell-mediated cytotoxicity","volume":"9","author":"Medvedev","year":"1997","journal-title":"Cytokine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","article-title":"High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome","volume":"1","author":"Hollander","year":"2017","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein\u2013Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data","volume":"70","author":"Glaser","year":"1997","journal-title":"Int J Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1200\/JCO.2005.02.6310","article-title":"Epstein\u2013Barr virus as a marker of survival after Hodgkin\u2019s lymphoma: a population-based study","volume":"23","author":"Keegan","year":"2005","journal-title":"J Clin Oncol"},{"key":"B92","first-page":"2114","article-title":"Expression of Epstein\u2013Barr virus latent membrane protein-1 in Hodgkin and Reed\u2013Sternberg cells of classical Hodgkin\u2019s lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome","volume":"9","author":"Herling","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B93","first-page":"660","article-title":"Normal natural killer cell activity in Hodgkin\u2019s disease patients in remission","volume":"69","author":"Douer","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1046\/j.1365-2141.2002.03478.x","article-title":"Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin\u2019s disease","volume":"117","author":"Porrata","year":"2002","journal-title":"Br J Haematol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/sj.bmt.1704050","article-title":"Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin\u2019s and non-Hodgkin\u2019s Lymphoma","volume":"31","author":"Gordan","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B96","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bmt.1703203","article-title":"Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation","volume":"28","author":"Porrata","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"B97","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1158\/1078-0432.CCR-09-0213","article-title":"Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin\u2019s lymphoma cells for natural killer cell-mediated cytotoxicity","volume":"15","author":"Boll","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejmech.2016.01.053","article-title":"Discovery of a new selective inhibitor of A disintegrin and metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin\u2019s lymphoma cell models","volume":"111","author":"Camodeca","year":"2016","journal-title":"Eur J Med Chem"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e27089","DOI":"10.4161\/onci.27089","article-title":"How to exploit stress-related immunity against Hodgkin\u2019s lymphoma: targeting ERp5 and ADAM sheddases","volume":"2","author":"Poggi","year":"2013","journal-title":"Oncoimmunology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"key":"B101","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"B105","doi-asserted-by":"publisher","first-page":"22310","DOI":"10.18632\/oncotarget.4208","article-title":"Regulation of split anergy in natural killer cells by inhibition of cathepsins C and H and cystatin F","volume":"6","author":"Magister","year":"2015","journal-title":"Oncotarget"},{"key":"B106","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy\u2014advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.2013.54.4379","article-title":"Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma","volume":"32","author":"van Nimwegen","year":"2014","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/annonc\/mdu130","article-title":"Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance dagger","volume":"25","author":"Daniels","year":"2014","journal-title":"Ann Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1200\/JCO.2016.67.7450","article-title":"Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: the impact on treatment outcome and social reintegration","volume":"34","author":"Behringer","year":"2016","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of second cancer in Hodgkin lymphoma survivors and influence of family history","volume":"35","author":"Sud","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00267\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T04:00:50Z","timestamp":1603857650000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00267\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2018.00267"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00267","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]},"article-number":"267"}}